Royal Bank of Canada Has $505.64 Million Stock Position in Boston Scientific Corporation $BSX

Key Points

• Royal Bank of Canada decreased its holdings in Boston Scientific Corporation by 13.2%, selling 763,662 shares in the 1st quarter, leaving it with approximately 0.34% ownership valued at $505.6 million.
• Several institutional investors are increasing their stakes, including Vanguard Group with a 1.3% lift and Goldman Sachs with a 10.8% increase in their shares owned.
• Boston Scientific reported an EPS of $0.75 for the last quarter, exceeding expectations, and has set a Q3 2025 guidance of 0.700-0.720 EPS.

Royal Bank of Canada lessened its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 13.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,012,262 shares of the medical equipment provider's stock after selling 763,662 shares during the period. Royal Bank of Canada owned about 0.34% of Boston Scientific worth $505,637,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the 1st quarter valued at $27,000. Investment Management Corp VA ADV acquired a new position in Boston Scientific during the 4th quarter worth about $25,000. Colonial Trust Co SC lifted its position in Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after buying an additional 260 shares in the last quarter. Sunbeam Capital Management LLC acquired a new position in Boston Scientific during the 4th quarter valued at about $26,000. Finally, Ameriflex Group Inc. acquired a new position in Boston Scientific during the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently commented on BSX shares. Leerink Partners started coverage on Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 price target for the company. UBS Group upped their price target on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Jefferies Financial Group reaffirmed a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Finally, Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Boston Scientific presently has an average rating of "Buy" and an average target price of $117.50.

Boston Scientific Stock Down 0.1%

Shares of BSX traded down $0.15 during mid-day trading on Friday, hitting $107.14. 4,062,435 shares of the company's stock were exchanged, compared to its average volume of 7,464,574. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $108.94. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a 50-day simple moving average of $104.76 and a 200 day simple moving average of $102.19. The company has a market cap of $158.76 billion, a PE ratio of 63.78, a P/E/G ratio of 2.59 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter last year, the firm posted $0.62 EPS. The company's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business's stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $18,397,457 over the last three months. Company insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.